Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.
The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow`s feet" and glabellar lines.
In a statement released today announcing the FDA approval, David Nicholson, the companys chief research and development officer said: Allergan recognizes that forehead lines are a top area of concern for patients.
(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers